Latest & greatest articles for adhd

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on adhd or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on adhd and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

ADHD

ADHD (or Attention deficit hyperactivity disorder) is a neurodevelopmental type mental disorder. It is characterised two main categories of two types of behavioural problems:

  • inattentiveness
  • hyperactivity and impulsiveness

Most people with ADHD have problems that fall into both categories, but it doesn’t have to be the case. If a person just has inattentiveness it is referred to as attention deficit disorder (ADD).

Methylphenidate is a commonly used medication used to treat patients suffering from attention-deficit hyperactivity disorder. Methylphenidate is part of a group of drugs known as stimulants. Central nervous system stimulants help change the amounts of natural substances in the brain. But it is not the only intervention; others include Bupropion, exercise and CBT (Cognitive behavioural therapy).

Extensive ADHD research and case studies have been carried out over numerous years. Trip has unrivalled coverage of the evidence base including systematic reviews, clinical trials, clinical guidelines and case studies.

Studies are ongoing to assess the safety and effectiveness of stimulants used on children with ADHD and intellectual disabilities as well as in other populations and other interventions. Trip also includes ongoing controlled trials and ongoing systematic reviews (via the PROSPERO database).

Top results for adhd

61. Efficacy and tolerability of methylphenidate and atomoxetine in the treatment of core symptoms of Attention Deficit Hyperkinetic Disorder (ADHD) in children and young people (CYP) with co-occurring ADHD and Autism Spectrum Disorder (ASD): a systematic rev

Efficacy and tolerability of methylphenidate and atomoxetine in the treatment of core symptoms of Attention Deficit Hyperkinetic Disorder (ADHD) in children and young people (CYP) with co-occurring ADHD and Autism Spectrum Disorder (ASD): a systematic rev Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content

2018 PROSPERO

62. Moderators of the effect of medication on working memory in youths diagnosed with ADHD: a systematic review and meta-analysis

Moderators of the effect of medication on working memory in youths diagnosed with ADHD: a systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne

2018 PROSPERO

63. Safety and efficacy of methylphenidate as treatment of combined attention deficit hyperactivity disorder (ADHD) and epilepsy in children and adolescents: systematic review

Safety and efficacy of methylphenidate as treatment of combined attention deficit hyperactivity disorder (ADHD) and epilepsy in children and adolescents: systematic review Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation

2018 PROSPERO

64. The efficacy of phosphatidylserine in the treatment of pediatric attention-deficit/hyperactivity disorder (ADHD): a systematic review and meta-analysis

The efficacy of phosphatidylserine in the treatment of pediatric attention-deficit/hyperactivity disorder (ADHD): a systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith

2018 PROSPERO

65. Childhood neglect in attention deficit hyperactivity disorder (ADHD): a systematic review and meta-analysis

Childhood neglect in attention deficit hyperactivity disorder (ADHD): a systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne") for correspondence: Organisation

2018 PROSPERO

66. Sustained effects of neurofeedback and methylphenidate in ADHD children: meta-analysis

Sustained effects of neurofeedback and methylphenidate in ADHD children: meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne") for correspondence: Organisation web address: Timing

2018 PROSPERO

67. Are ADHD medications under or over prescribed worldwide? Protocol for a systematic review and meta-analysis

Are ADHD medications under or over prescribed worldwide? Protocol for a systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne") for correspondence: Organisation

2018 PROSPERO

68. Association between exposure to pesticides and ADHD or ASD symptoms: a systematic review

Association between exposure to pesticides and ADHD or ASD symptoms: a systematic review Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne") for correspondence: Organisation web address: Timing

2018 PROSPERO

69. Noradrenaline reuptake inhibitors (NRIs) for attention deficit hyperactivity disorder (ADHD) in adults [Cochrane protocol]

Noradrenaline reuptake inhibitors (NRIs) for attention deficit hyperactivity disorder (ADHD) in adults [Cochrane protocol] Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne") for correspondence

2018 PROSPERO

70. Interventions to enhance teachers' knowledge and attitudes towards ADHD to support them in dealing with children with ADHD in the classroom: a systematic review

Interventions to enhance teachers' knowledge and attitudes towards ADHD to support them in dealing with children with ADHD in the classroom: a systematic review Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr

2018 PROSPERO

71. Resting-state network dysconnectivity in ADHD: a system-neuroscience-based meta-analysis

Resting-state network dysconnectivity in ADHD: a system-neuroscience-based meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne") for correspondence: Organisation web address: Timing

2018 PROSPERO

72. Bupropion for attention deficit hyperactivity disorder (ADHD) in adults. (PubMed)

Bupropion for attention deficit hyperactivity disorder (ADHD) in adults. Attention deficit hyperactivity disorder (ADHD) is a prevalent neurobiological condition, characterised by behavioral and cognitive symptoms such as inattention, impulsivity and/or excessive activity. The syndrome is commonly accompanied by psychiatric comorbidities and is associated with educational and occupational underachievement.Although psychostimulant medications are the mainstay of treatment for ADHD, not all (...) adults respond optimally to, or can tolerate, these medicines. Thus, alternative non-stimulant treatment approaches for ADHD have been explored. One of these alternatives is bupropion, an aminoketone antidepressant and non-competitive antagonism of nicotinic acetylcholine receptors. Bupropion is registered for the treatment of depression and smoking cessation, but is also used off-label to treat ADHD.To assess the effects and safety of bupropion for the treatment of adults with ADHD.We searched

Full Text available with Trip Pro

2017 Cochrane

73. Attention deficit hyperactivity disorder (ADHD): avoid guanfacine

Attention deficit hyperactivity disorder (ADHD): avoid guanfacine Prescrire IN ENGLISH - Spotlight ''Attention deficit hyperactivity disorder (ADHD): avoid guanfacine'', 1 October 2017 {1} {1} {1} | | > > > Attention deficit hyperactivity disorder (ADHD): avoid guanfacine Spotlight Every month, the subjects in Prescrire’s Spotlight. 100 most recent :  |   |   |   |   |   |   |   |   |  Spotlight Attention deficit (...) hyperactivity disorder (ADHD): avoid guanfacine In children diagnosed with attention deficit hyperactivity disorder (ADHD), guanfacine has no proven efficacy in improving family and social relationships. On the other hand, it has frequent, sometimes severe, adverse effects. In practice, it is best to avoid guanfacine. The diagnosis of attention deficit hyperactivity disorder in children is based on non-specific behavioural symptoms: inattentiveness, hyperactivity and impulsiveness. The disruptive impact

2017 Prescrire

74. A systematic review ofÿthe effectiveness ofÿmotor interventions for ADHD

A systematic review ofÿthe effectiveness ofÿmotor interventions for ADHD Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne") for correspondence: Organisation web address: Timing and effect

2017 PROSPERO

75. Attentin (dexamfetamine) - attention deficit/hyperactivity disorder (ADHD)

Attentin (dexamfetamine) - attention deficit/hyperactivity disorder (ADHD) Attentin (dexamfetamine) × Insert searchphrase to search the website Insert searchphrase to search the website > > > Attentin (dexamfetamine) Conclusion Attentin (dexamfetamine) is a CNS stimulant agent for treatment of attention deficit/hyperactivity disorder (ADHD) in children and adolescents aged 6-17 years. Attentin can be used second-line when response to methylphenidate is not sufficiently effective or has caused (...) unacceptable adverse reactions. The indication for medicinal treatment of ADHD is made by a specialist in child and adolescent psychiatry upon which further treatment (maintenance treatment) may be decided by the general practitioner in collaboration with a child and adolescent psychiatrist (1). Pharmaceutical treatment should not be the only treatment for ADHD, but should be combined with non-pharmaceutical interventions (1). The effect of dexamfetamine on ADHD core symptoms in children and adults has

2017 Danish Pharmacotherapy Reviews

76. Intuniv (guanfacine) - ADHD

Intuniv (guanfacine) - ADHD Intuniv® (guanfacine) × Insert searchphrase to search the website Insert searchphrase to search the website > > > Intuniv® (guanfacine) Conclusion With Intuniv (guanfacine), a new type of non-stimulant ADHD medication is introduced. Intuniv is approved for the treatment of ADHD in children and adolescents when central nervous stimulants are not suitable, not tolerated or have no effect. Thus, Intuniv has a more restrictive indication compared to the other non (...) -stimulant ADHD medicine, atomoxetine. Compared to placebo, Intuniv has an effect on ADHD core symptoms with medium effect size. It suggests that the effect of Intuniv is lower than that of methylphenidate, but comparable to or higher than that of atomoxetine. No convincing effect on functioning has been established. Adverse reactions and risks of interactions are significant and may be serious; especially sedation and somnolence are common and influence Intuniv's effect on ADHD core symptoms. Intuniv

2017 Danish Pharmacotherapy Reviews

77. ADHD Medication and Substance-Related Problems

ADHD Medication and Substance-Related Problems Substance use disorders are major contributors to excess mortality among individuals with attention deficit hyperactivity disorder (ADHD), yet associations between pharmacological ADHD treatment and substance-related problems remain unclear. This study investigated concurrent and long-term associations between ADHD medication treatment and substance-related events.The authors analyzed 2005-2014 commercial health care claims from 2,993,887 (47.2 (...) % female) adolescent and adult ADHD patients. Within-individual analyses compared the risk of substance-related events (i.e., emergency department visits related to substance use disorders) during months in which patients received prescribed stimulant medication or atomoxetine relative to the risk during months in which they did not.In adjusted within-individual comparisons, relative to periods in which patients did not receive ADHD medication, male patients had 35% lower odds of concurrent substance

Full Text available with Trip Pro

2017 EvidenceUpdates

78. Effectiveness of methylphenidate and PUFA for the treatment of patients with ADHD: A double-blinded randomized clinical trial (PubMed)

Effectiveness of methylphenidate and PUFA for the treatment of patients with ADHD: A double-blinded randomized clinical trial In some children with ADHD, sub-optimal levels of various nutrients including PUFA especially omega-3 has been observed, and contradictory reports exist on the results of studies conducted on the positive therapeutic effects of PUFA in patients with ADHD.The aim of this study was to investigate the effectiveness of methylphenidate and PUFA on treatment of patients (...) with ADHD in Zahedan, Iran.In this clinical trial, 40 children between 6 and 12 years of age with ADHD were investigated in Zahedan in 2014. Patients were randomly divided into two groups of methylphenidate plus PUFA and methylphenidate plus placebo. ADHD rating scale was filled before and after the study for patients of both groups. Finally, data were analyzed using SPSS18, paired-samples t-test and chi-square.Mean age of patients was 2.9±1.8 years. Thirty-three children (82.5%) were boys and seven

Full Text available with Trip Pro

2017 Electronic physician Controlled trial quality: uncertain

79. Occupational therapy for attention-deficit/hyperactivity disorder (ADHD)

Occupational therapy for attention-deficit/hyperactivity disorder (ADHD) Occupational therapy for attention-deficit/hyperactivity disorder (ADHD) Occupational therapy for attention-deficit/hyperactivity disorder (ADHD) HAYES, Inc Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation HAYES, Inc. Occupational therapy for attention-deficit/hyperactivity disorder (ADHD (...) ) Lansdale: HAYES, Inc. Directory Publication. 2017 Authors' conclusions Occupational therapy (OT) for attention-deficit/hyperactivity disorder (ADHD) encompasses a wide array of interventions, with the aim of increasing function in all aspects of life and settings (school, home, etc.). Specific interventions vary and are determined by the occupational therapist depending on the presenting problems, deficits, and the therapist's determination of the best course of treatment. OT interventions for ADHD can

2017 Health Technology Assessment (HTA) Database.

80. Pharmacotherapy of emotional dysregulation in adults with ADHD: protocol for a systematic review and meta-analysis

Pharmacotherapy of emotional dysregulation in adults with ADHD: protocol for a systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne") for correspondence

2017 PROSPERO